These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21318601)

  • 1. Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.
    Gluz O; Wild P; Liedtke C; Kates R; Mendrik H; Ehm E; Artinger V; Diallo-Danebrock R; Ting E; Mohrmann S; Poremba C; Harbeck N; Nitz U; Hartmann A; Gaumann A
    Breast Cancer Res Treat; 2011 Apr; 126(3):643-51. PubMed ID: 21318601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
    Basilio-de-Oliveira RP; Pannain VL
    World J Gastroenterol; 2015 Jun; 21(22):6924-30. PubMed ID: 26078569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer.
    Zhou S; Wang GP; Liu C; Zhou M
    BMC Cancer; 2006 Sep; 6():231. PubMed ID: 17010208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
    Rubatt JM; Darcy KM; Hutson A; Bean SM; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
    Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome.
    Dales JP; Garcia S; Andrac L; Carpentier S; Ramuz O; Lavaut MN; Allasia C; Bonnier P; Charpin C
    Int J Oncol; 2004 May; 24(5):1197-204. PubMed ID: 15067342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity.
    Gluz O; Wild P; Meiler R; Diallo-Danebrock R; Ting E; Mohrmann S; Schuett G; Dahl E; Fuchs T; Herr A; Gaumann A; Frick M; Poremba C; Nitz UA; Hartmann A
    Int J Cancer; 2008 Sep; 123(6):1433-8. PubMed ID: 18561322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy.
    Diallo-Danebrock R; Ting E; Gluz O; Herr A; Mohrmann S; Geddert H; Rody A; Schaefer KL; Baldus SE; Hartmann A; Wild PJ; Burson M; Gabbert HE; Nitz U; Poremba C
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):488-97. PubMed ID: 17255270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis.
    Dubinski W; Gabril M; Iakovlev VV; Scorilas A; Youssef YM; Faragalla H; Kovacs K; Rotondo F; Metias S; Arsanious A; Plotkin A; Girgis AH; Streutker CJ; Yousef GM
    Hum Pathol; 2012 Jul; 43(7):1037-43. PubMed ID: 22204709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
    Erber R; Gluz O; Brünner N; Kreipe HH; Pelz E; Kates R; Bartels A; Huober J; Mohrmann S; Moustafa Z; Liedtke C; Möbus V; Augustin D; Thomssen C; Jänicke F; Kiechle M; Kuhn W; Nitz U; Harbeck N; Hartmann A
    Breast Cancer Res Treat; 2015 Apr; 150(2):279-88. PubMed ID: 25721604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microvessel Landscape Assessment in Pancreatic Ductal Adenocarcinoma: Unclear Value of Targeting Endoglin (CD105) as Prognostic Factor of Clinical Outcome.
    Lytras D; Leontara V; Kefala M; Foukas PG; Giannakou N; Pouliakis A; Dervenis C; Panayiotides IG; Karakitsos P
    Pancreas; 2015 Jan; 44(1):87-92. PubMed ID: 25058886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic and predictive impact of protein expression profiling in high risk breast cancer patients treated with high-dose chemotherapy].
    Diallo-Danebrock R; Ting E; Gluz O; Herr A; Mohrmann S; Geddert H; Gabbert HE; Nitz U; Poremba C
    Verh Dtsch Ges Pathol; 2007; 91():187-96. PubMed ID: 18314614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma.
    Behrem S; Zarkovic K; Eskinja N; Jonjic N
    Croat Med J; 2005 Jun; 46(3):417-22. PubMed ID: 15861521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers].
    Charpin-Taranger C; Dales JP; Garcia S; Andrac-Meyer L; Ramuz O; Carpentier-Meunier S; Bonnier P
    Bull Acad Natl Med; 2003; 187(6):1129-45; discussion 1145-6. PubMed ID: 14978873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoglin (CD 105) as a potential prognostic factor in neuroblastoma.
    Ćavar S; Jelašić D; Seiwerth S; Milošević M; Hutinec Z; Mišić M
    Pediatr Blood Cancer; 2015 May; 62(5):770-5. PubMed ID: 25683142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor-beta binding receptor endoglin (CD105) expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence.
    Bellone G; Solerio D; Chiusa L; Brondino G; Carbone A; Prati A; Scirelli T; Camandona M; Palestro G; Dei Poli M
    Ann Surg Oncol; 2007 Nov; 14(11):3232-42. PubMed ID: 17682823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD105 expression is an independent predictor of survival in patients with endometrial cancer.
    Erdem O; Taskiran C; Onan MA; Erdem M; Guner H; Ataoglu O
    Gynecol Oncol; 2006 Dec; 103(3):1007-11. PubMed ID: 16854456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival.
    Davidson B; Stavnes HT; Førsund M; Berner A; Staff AC
    Breast; 2010 Dec; 19(6):493-8. PubMed ID: 21078485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.
    Randall LM; Monk BJ; Darcy KM; Tian C; Burger RA; Liao SY; Peters WA; Stock RJ; Fruehauf JP
    Gynecol Oncol; 2009 Mar; 112(3):583-9. PubMed ID: 19110305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma.
    Saad RS; El-Gohary Y; Memari E; Liu YL; Silverman JF
    Hum Pathol; 2005 Sep; 36(9):955-61. PubMed ID: 16153457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.